Medicare GLP-1 Bridge Program: What Beneficiaries Need to Know

The Medicare GLP-1 Bridge Program is still ongoing. Launched July 1, 2026, the temporary program provides eligible Medicare beneficiaries access to certain GLP-1 medications for weight management for $50 per month, including Foundayo®, Wegovy® (injection and tablets), and Zepbound® (KwikPen®). The program is scheduled to continue through December 31, 2027.

Medicare has established eligibility criteria. To be eligible, beneficiaries must be enrolled in a Medicare prescription drug plan, including:

• Medicare Part D

• Medicare Advantage (Part C) with prescription drug coverage

• A Special Needs Plan (SNP)

• An Employer/Union Group Waiver Plan (EGWP)

• The Limited Income Newly Eligible Transition (LI NET) Program

  
  

Additionally, beneficiaries must be 18 years of age or older and meet one of the following criteria:

• BMI of 35 kg/m² or higher; or

• BMI of 30 kg/m² or higher with at least one comorbidity, such as diastolic heart failure, hypertension, or chronic kidney disease (stage 3a or higher); or

• BMI of 27 kg/m² or higher with prediabetes, a history of myocardial infarction (heart attack) or stroke, or symptomatic peripheral artery disease.

  
  

Beneficiaries are not eligible if they already have Medicare Part D coverage for GLP-1 medications or have type 2 diabetes, fatty liver disease, or moderate-to-severe sleep apnea.

Please inform patients who may benefit from the program and encourage them to speak with their healthcare provider or pharmacist to determine whether they may be eligible.